Symbols / TCRX $1.25 -1.57% TScan Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
TCRX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 75.13M Enterprise Value 14.00M Income -129.77M Sales 10.32M Book/sh 2.16 Cash/sh 2.68
Dividend Yield — Payout 0.00% Employees 142 IPO — P/E — Forward P/E -1.63
PEG — P/S 7.28 P/B 0.58 P/C — EV/EBITDA -0.11 EV/Sales 1.36
Quick Ratio 8.15 Current Ratio 8.41 Debt/Eq 76.46 LT Debt/Eq — EPS (ttm) -1.00 EPS next Y -0.77
EPS Growth — Revenue Growth 286.00% Earnings 2026-03-04 ROA -27.88% ROE -71.28% ROIC —
Gross Margin 0.00% Oper. Margin -8.52% Profit Margin 0.00% Shs Outstand 55.82M Shs Float 47.79M Short Float 4.03%
Short Ratio 3.16 Short Interest — 52W High 2.57 52W Low 0.88 Beta 1.01 Avg Volume 778.22K
Volume 740.62K Target Price $6.00 Recom Strong_buy Prev Close $1.27 Price $1.25 Change -1.57%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$1.25
Latest analyst target
3. DCF / Fair value
$-31.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.25
Low
$5.00
High
$7.00
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-05 main Wedbush Outperform → Outperform $5
2025-11-13 main HC Wainwright & Co. Buy → Buy $7
2025-11-04 down BTIG Buy → Neutral —
2025-11-04 main Needham Buy → Buy $6
2025-05-07 main HC Wainwright & Co. Buy → Buy $10
2025-04-08 reit Needham Buy → Buy $9
2025-03-07 main Barclays Overweight → Overweight $3
2025-03-06 reit HC Wainwright & Co. Buy → Buy $15
2025-03-05 main Needham Buy → Buy $9
2024-12-11 reit HC Wainwright & Co. Buy → Buy $15
2024-12-11 reit Needham Buy → Buy $11
2024-11-15 reit HC Wainwright & Co. Buy → Buy $15
2024-11-12 reit Needham Buy → Buy $11
2024-11-06 reit Needham Buy → Buy $11
2024-08-13 reit Wedbush Outperform → Outperform $10
2024-08-13 reit HC Wainwright & Co. Buy → Buy $15
2024-08-12 reit Needham Buy → Buy $11
2024-06-04 reit HC Wainwright & Co. Buy → Buy $15
2024-05-16 init BTIG — → Buy $12
2024-05-14 reit HC Wainwright & Co. Buy → Buy $15
News
RSS: Latest TCRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-23 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 161,801 $0.90 $145,526
2025-05-20 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 2,588,794 $1.20 $3,106,553
2024-12-13 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 131,800 $2.90 $385,769
2024-11-15 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 947 $4.34 $4,114
2024-09-23 KLENCKE BARBARA M.D. Director — 5,000 $5.29 $26,450
2024-08-26 KLENCKE BARBARA M.D. Director — 10,000 $5.53 $56,100
2024-08-23 ZDRAVESKI ZORAN Officer — 164,686 $5.78 $952,116
2024-08-23 ZDRAVESKI ZORAN Officer — 157,186 $1.81 $531,520
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
10.32
+266.65%
2.82
-86.62%
21.05
+55.52%
13.54
Operating Revenue
10.32
+266.65%
2.82
-86.62%
21.05
+55.52%
13.54
Operating Expense
146.14
+6.18%
137.64
+20.20%
114.51
+42.83%
80.17
Research And Development
114.15
+6.33%
107.35
+21.78%
88.15
+47.37%
59.82
Selling General And Administration
31.33
+6.00%
29.56
+15.95%
25.49
+25.26%
20.35
General And Administrative Expense
31.33
+6.00%
29.56
+15.95%
25.49
+25.26%
20.35
Salaries And Wages
17.16
+9.96%
15.60
+36.90%
11.40
-2.21%
11.65
Other Gand A
14.18
+1.57%
13.96
-0.99%
14.10
+62.05%
8.70
Total Expenses
146.14
+6.18%
137.64
+20.20%
114.51
+42.83%
80.17
Operating Income
-135.81
-0.74%
-134.82
-44.26%
-93.46
-40.25%
-66.64
Total Operating Income As Reported
-135.81
-0.74%
-134.82
-44.26%
-93.46
-40.25%
-66.64
EBITDA
-124.13
-3.67%
-119.74
-49.49%
-80.10
-33.70%
-59.91
Normalized EBITDA
-124.13
-4.62%
-118.65
-48.13%
-80.10
-33.70%
-59.91
Reconciled Depreciation
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
EBIT
-127.00
-2.54%
-123.85
-44.92%
-85.46
-31.38%
-65.05
Total Unusual Items
0.00
+100.00%
-1.09
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-1.09
0.00
—
Special Income Charges
0.00
+100.00%
-1.09
0.00
—
Other Special Charges
—
1.09
—
—
Net Income
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Pretax Income
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Non Operating Interest Income Expense
6.05
-28.11%
8.41
+98.40%
4.24
+921.69%
0.41
Interest Expense Non Operating
2.77
-24.20%
3.65
-2.82%
3.76
+219.64%
1.18
Net Interest Income
6.05
-28.11%
8.41
+98.40%
4.24
+921.69%
0.41
Interest Expense
2.77
-24.20%
3.65
-2.82%
3.76
+219.64%
1.18
Interest Income Non Operating
8.82
-26.93%
12.06
+50.83%
8.00
+402.77%
1.59
Interest Income
8.82
-26.93%
12.06
+50.83%
8.00
+402.77%
1.59
Other Income Expense
—
-1.09
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Income From Continuing Operation Net Minority Interest
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Income From Continuing And Discontinued Operation
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Income Continuous Operations
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Normalized Income
-129.77
-2.66%
-126.41
-41.69%
-89.22
-34.73%
-66.22
Net Income Common Stockholders
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Diluted EPS
-1.00
+12.28%
-1.14
+16.18%
-1.36
+50.55%
-2.75
Basic EPS
-1.00
+12.28%
-1.14
+16.18%
-1.36
+50.55%
-2.75
Basic Average Shares
129.78
+15.88%
111.99
+70.72%
65.60
+172.78%
24.05
Diluted Average Shares
129.78
+15.88%
111.99
+70.72%
65.60
+172.78%
24.05
Diluted NI Availto Com Stockholders
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Depreciation Amortization Depletion Income Statement
0.66
-9.89%
0.73
-15.55%
0.86
—
Depreciation And Amortization In Income Statement
0.66
-9.89%
0.73
-15.55%
0.86
—
Depreciation Income Statement
0.66
-9.89%
0.73
-15.55%
0.86
—
Total Other Finance Cost
—
—
—
—
Line Item Trend 2023-12-31 2021-12-31
Total Assets
272.15
—
Current Assets
194.24
—
Cash Cash Equivalents And Short Term Investments
192.04
—
Cash And Cash Equivalents
133.36
—
Other Short Term Investments
58.69
—
Prepaid Assets
—
4.25
Other Current Assets
2.19
—
Total Non Current Assets
77.91
—
Net PPE
71.23
—
Gross PPE
85.83
—
Accumulated Depreciation
-14.60
—
Properties
0.00
—
Machinery Furniture Equipment
2.98
—
Construction In Progress
0.55
—
Other Properties
79.14
—
Leases
3.16
—
Non Current Prepaid Assets
—
0.17
Other Non Current Assets
6.68
—
Total Liabilities Net Minority Interest
121.28
—
Current Liabilities
29.82
—
Payables And Accrued Expenses
7.19
—
Payables
2.37
—
Accounts Payable
2.37
—
Current Accrued Expenses
4.81
—
Pensionand Other Post Retirement Benefit Plans Current
5.48
—
Current Debt And Capital Lease Obligation
6.59
—
Current Debt
3.35
—
Other Current Borrowings
3.35
—
Current Capital Lease Obligation
3.25
—
Current Deferred Liabilities
10.14
—
Current Deferred Revenue
10.14
—
Other Current Liabilities
0.42
—
Total Non Current Liabilities Net Minority Interest
91.46
—
Long Term Debt And Capital Lease Obligation
85.84
—
Long Term Debt
26.70
—
Long Term Capital Lease Obligation
59.14
—
Non Current Deferred Liabilities
5.62
—
Non Current Deferred Revenue
5.62
—
Other Non Current Liabilities
—
0.10
Stockholders Equity
150.87
—
Common Stock Equity
150.87
—
Capital Stock
0.01
—
Common Stock
0.01
—
Preferred Stock
0.00
—
Share Issued
47.83
—
Ordinary Shares Number
47.83
—
Treasury Shares Number
0.00
-100.00%
0.12
Additional Paid In Capital
398.46
—
Retained Earnings
-247.60
—
Gains Losses Not Affecting Retained Earnings
0.00
—
Other Equity Adjustments
—
—
Total Equity Gross Minority Interest
150.87
—
Total Capitalization
177.57
—
Working Capital
164.42
—
Invested Capital
180.91
—
Total Debt
92.43
—
Capital Lease Obligations
62.39
—
Net Tangible Assets
150.87
—
Tangible Book Value
150.87
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-135.32
-22.10%
-110.82
-80.62%
-61.36
+7.74%
-66.50
Cash Flow From Continuing Operating Activities
-135.32
-22.10%
-110.82
-80.62%
-61.36
+7.74%
-66.50
Net Income From Continuing Operations
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Depreciation Amortization Depletion
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
Depreciation
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
Depreciation And Amortization
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
Other Non Cash Items
0.46
-40.23%
0.77
+2.11%
0.76
+191.15%
0.26
Stock Based Compensation
11.71
+22.59%
9.55
+83.35%
5.21
+14.44%
4.55
Operating Gains Losses
—
1.09
—
—
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-18.18
-459.68%
5.05
-71.29%
17.61
+272.10%
-10.23
Change In Prepaid Assets
-0.53
+2.42%
-0.54
-154.62%
0.98
+340.24%
-0.41
Change In Payables And Accrued Expense
-10.24
-256.86%
6.53
+71.69%
3.80
+201.67%
1.26
Change In Accrued Expense
-7.23
-259.44%
4.53
+17.62%
3.85
+426.37%
0.73
Change In Payable
-3.01
-251.00%
1.99
+3934.62%
-0.05
-109.85%
0.53
Change In Account Payable
-3.01
-251.00%
1.99
+3934.62%
-0.05
-109.85%
0.53
Change In Other Working Capital
-7.42
-694.00%
-0.93
-107.29%
12.82
+215.70%
-11.08
Investing Cash Flow
109.37
+307.88%
-52.61
+13.41%
-60.76
-1338.08%
-4.22
Cash Flow From Continuing Investing Activities
109.37
+307.88%
-52.61
+13.41%
-60.76
-1338.08%
-4.22
Net PPE Purchase And Sale
-4.41
-15.22%
-3.83
-21.58%
-3.15
+25.54%
-4.22
Purchase Of PPE
-4.41
-15.22%
-3.83
-21.58%
-3.15
+25.54%
-4.22
Capital Expenditure
-4.41
-15.22%
-3.83
-21.58%
-3.15
+25.54%
-4.22
Net Investment Purchase And Sale
113.78
+333.21%
-48.79
+15.32%
-57.61
0.00
Purchase Of Investment
-87.47
+63.77%
-241.44
-211.09%
-77.61
0.00
Sale Of Investment
201.25
+4.46%
192.66
+863.29%
20.00
0.00
Financing Cash Flow
-0.34
-100.16%
208.76
+54.13%
135.44
+361.38%
29.36
Cash Flow From Continuing Financing Activities
-0.34
-100.16%
208.76
+54.13%
135.44
+361.38%
29.36
Net Issuance Payments Of Debt
0.00
-100.00%
15.31
0.00
-100.00%
29.35
Issuance Of Debt
0.00
-100.00%
32.46
0.00
-100.00%
29.35
Repayment Of Debt
0.00
+100.00%
-17.14
0.00
—
Long Term Debt Issuance
0.00
-100.00%
32.46
0.00
-100.00%
29.35
Long Term Debt Payments
0.00
+100.00%
-17.14
0.00
—
Net Long Term Debt Issuance
0.00
-100.00%
15.31
0.00
-100.00%
29.35
Net Common Stock Issuance
0.00
-100.00%
33.13
-21.89%
42.41
+21876.17%
0.19
Cash Dividends Paid
0.00
0.00
—
—
Proceeds From Stock Option Exercised
0.26
-99.84%
160.32
+72.33%
93.03
+69846.62%
0.13
Net Other Financing Charges
-0.40
—
—
-0.32
Changes In Cash
-26.28
-157.98%
45.33
+240.16%
13.33
+132.21%
-41.37
Beginning Cash Position
183.72
+32.76%
138.39
+10.66%
125.06
-24.86%
166.44
End Cash Position
157.44
-14.31%
183.72
+32.76%
138.39
+10.66%
125.06
Free Cash Flow
-139.73
-21.87%
-114.65
-77.74%
-64.50
+8.80%
-70.73
Interest Paid Supplemental Data
2.31
-19.92%
2.88
-4.03%
3.00
+354.85%
0.66
Amortization Of Securities
-2.41
+38.18%
-3.90
-263.53%
-1.07
0.00
Common Stock Issuance
0.00
-100.00%
33.13
-21.89%
42.41
+21876.17%
0.19
Interest Paid CFF
-0.20
0.00
—
—
Issuance Of Capital Stock
0.00
-100.00%
33.13
-21.89%
42.41
+21876.17%
0.19
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category